Literature DB >> 21680949

Systemic steroids in severe sepsis and septic shock.

Gourang P Patel1, Robert A Balk.   

Abstract

Despite more than 5 decades of study and debate, the role of corticosteroid treatment in patients with severe sepsis and septic shock remains controversial. Data support a beneficial effect on systemic blood pressure in patients with septic shock. However, the ability of corticosteroid therapy to improve mortality in patients with severe sepsis and septic shock remains controversial, with contradictory results from recent large multicenter clinical trials. Although it appears clear that high-dose corticosteroid treatment provides no benefit and possibly harm in septic patients, the experimental design flaws and biases of recent low-dose (physiologic) steroid treatment trials limit their ability to provide adequate answers to the important questions of which septic patients should be treated, how much steroid to give, and the optimum duration of treatment. Unfortunately, the answer to these important questions is not readily evident based on the current evidence or the application of metaanalysis to the available clinical data. This concise evidence-based review highlights the strengths and weaknesses of the current data to inform the practicing clinician as to which patients are likely to derive significant benefit from corticosteroid treatment, while we await more definitive guidance from future multicenter, prospective, randomized, controlled trials designed to better answer these important therapeutic questions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680949     DOI: 10.1164/rccm.201011-1897CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  42 in total

1.  Corticosteroids are associated with repression of adaptive immunity gene programs in pediatric septic shock.

Authors:  Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

2.  Randomized controlled trials and practice guidelines: the good, the bad, and the ugly.

Authors:  Charles L Sprung
Journal:  Intensive Care Med       Date:  2012-10-12       Impact factor: 17.440

Review 3.  Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design.

Authors:  Hallie C Prescott; Carolyn S Calfee; B Taylor Thompson; Derek C Angus; Vincent X Liu
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

Review 4.  Cross-talk between HPA-axis-increased glucocorticoids and mitochondrial stress determines immune responses and clinical manifestations of patients with sepsis.

Authors:  Emiko Kasahara; Masayasu Inoue
Journal:  Redox Rep       Date:  2014-10-13       Impact factor: 4.412

5.  Evaluation of Practice Changes in the Care of Patients with Septic Shock during the U.S. Norepinephrine Shortage.

Authors:  Hannah Wunsch; May Hua; Allan J Walkey; Gordon Rubenfeld; Emily Vail; Hayley B Gershengorn
Journal:  Ann Am Thorac Soc       Date:  2018-04

6.  Endotype Transitions During the Acute Phase of Pediatric Septic Shock Reflect Changing Risk and Treatment Response.

Authors:  Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie C Fitzgerald; Paul A Checchia; Keith Meyer; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Riad Lutfi; Shira Gertz; Jocelyn R Grunwell; Christopher J Lindsell
Journal:  Crit Care Med       Date:  2018-03       Impact factor: 7.598

7.  Glucocorticoid receptor isoform-specific regulation of development, circadian rhythm, and inflammation in mice.

Authors:  Robert H Oakley; Sivapriya Ramamoorthy; Julie F Foley; Jonathan T Busada; Nick Z Lu; John A Cidlowski
Journal:  FASEB J       Date:  2018-04-19       Impact factor: 5.191

8.  Developing a clinically feasible personalized medicine approach to pediatric septic shock.

Authors:  Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Raj S Shekhar; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Eileen Beckman; Erin Frank; Christopher J Lindsell
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 9.  Septic Shock: Advances in Diagnosis and Treatment.

Authors:  Christopher W Seymour; Matthew R Rosengart
Journal:  JAMA       Date:  2015-08-18       Impact factor: 56.272

10.  Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF-α and TGF-β1) in murine model.

Authors:  Asha Kumari; D Dash; Rashmi Singh
Journal:  Inflammopharmacology       Date:  2017-03-13       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.